Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Lancet. Psychiatry|December 21, 2019
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysisToby Pillinger, Robert A McCutcheon, Luke Vano, et al.
Psychiatry Investigation|July 29, 2022
The Relationship Between Frontostriatal Connectivity and Striatal Dopamine Function in Schizophrenia: An 18F-DOPA PET and Diffusion Tensor Imaging Study in Treatment Responsive and Resistant PatientsSangho Shin, Wi Hoon Jung, Robert McCutcheon, et al.
Schizophrenia Bulletin|December 20, 2015
Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-ResponsiveElias Mouchlianitis, Michael A P Bloomfield, Vincent Law, et al.
JAMA Network Open|May 22, 2020
Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysisKatherine Beck, Guy Hindley, Faith Borgan, et al.
Psychological Medicine|September 19, 2017
Brain-relevant antibodies in first-episode psychosis: a matched case-control studyFiona Gaughran, John Lally, Katherine Beck, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|June 8, 2021
The Effects of Acute Δ9-Tetrahydrocannabinol on Striatal Glutamatergic Function: A Proton Magnetic Resonance Spectroscopy StudyMichael A P Bloomfield, Katherine Petrilli, Rachel Lees, et al.
Schizophrenia Bulletin|May 11, 2026
Variability and Magnitude of Choline Levels Across the Psychosis Spectrum: A Meta-analysisJack B Fanshawe, Cameron J Watson, Valentina Mancini, et al.
Translational Psychiatry|August 13, 2021
N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging studyKatherine Beck, Atheeshaan Arumuham, Mattia Veronese, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 9, 2026
Does a monoclonal antibody targeting immune cells affect glutamatergic level in schizophrenia? A multimodal PET/MRS brain imaging studyGuy Hindley, Yuya Mizuno, Katherine Beck, et al.
ACS Chemical Neuroscience|October 23, 2018
Comment on " In Vivo [18F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primates"Colm J McGinnity, Erik Årstad, Katherine Beck, et al.
Pageof 4